A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have lost about 23.4% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
Hosted on MSN
BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating
BofA Securities analysts on Wednesday lifted ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s price target to $23 from $18, while maintaining a Neutral rating for its shares. A research scientist looking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results